Patent ID: 8916584

Claim:
A method for the treatment of Parkinson's disease, parkinsonism, and disease states involving akinesia or bradykinesia in a mammal comprising the step of administering to the mammal at least one compound in a dosage and amount effective to treat the dysfunction in the mammal, the compound having a structure represented by a formula: wherein: A is aryl or heteroaryl or a 3-8 membered ring comprising C, O, S, and/or N; R is selected from hydrogen, halogen, C 1-10 alkyl, C 3-10 cycloalkyl, OC 1-10 alkyl (which may contain a C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 ), NR 3 R 4 , CONR 3 R 4 , S(O) 0-2 NR 3 R 4 , CN or CF 3 ; R 1 is independently selected from hydrogen, halogen, C 1-10 alkyl, C 3-10 cycloalkyl, OC 1-10 alkyl (which may contain a C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 ), NR 3 R 4 , CR 3 R 4 , CONR 3 R 4 , S(O) 0-2 NR 3 R 4 , CN; CF 3 , or S(O) 0-2 C 1-10 alkyl (which may contain a C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 ), COC 1-10 alkyl; R 2 is independently selected from hydrogen, halogen, C 1-10 alkyl, C 3-10 cycloalkyl, OC 1-10 alkyl (which may contain a C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 ), NR 3 R 4 , CR 3 R 4 , CONR 3 R 4 , S(O) 0-2 NR 3 R 4 , CN or CF 3 , or S(O) 0-2 C 1-10 alkyl (which may contain a C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 ), COC 1-10 alkyl; R 1 and R 2 can optionally cyclize to form a ring comprising C 3 -C 12 cycloalkyl or C 3 -C 12 cycloalkenyl or aryl or heteroaryl or C 3 -C 12 heterocycloalkyl or 3-8 membered ring comprising C, O, S, and/or N, optionally substituted with one or more R 4 ; R 3 is selected from hydrogen, C 1-6 alkyl, C 3-10 cycloalkyl, aryl, benzyl, heteroaryl, halogen, CN, CF 3 ; R 4 is selected from hydrogen, C 1-6 alkyl, C 3-10 cycloalkyl, aryl, benzyl, heteroaryl, halogen, CN, CF 3 ; R 3 and R 4 can optionally cyclize to form a ring comprising C 3 -C 12 cycloalkyl or C 3 -C 12 cycloalkenyl or aryl or heteroaryl or C 3 -C 12 heterocycloalkyl or 3-8 membered ring comprising C, O, S, and/or N, optionally substituted with one or more R 5 ; R 5 is selected from hydrogen, halogen, OC 1-10 alkyl (which may contain a C 3-8 membered ring containing C, O, S or N, optionally substituted with one or more R 4 ), CN, CF 3 ; provided that R 1 cannot be CF 3 when R 2 is H and R 2 cannot be CF 3 when R 1 is H; or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable derivative thereof.